首页 > 最新文献

Clinical Kidney Journal最新文献

英文 中文
Association of serum zinc with mineral stress in chronic kidney disease. 慢性肾病患者血清锌与矿物质压力的关系
IF 4.6 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-20 DOI: 10.1093/ckj/sfae258
Azmat Sohail,Jakob Obereigner,Gregor Mitter,Thomas Schmid,Anna-Sofie Hofer,Gerhard Schuster,Astrid Hügl,Angelika H Dorninger,Markus Mandl,Andreas Pasch,Helmut K Lackner,Ilona Papousek,Benjamin Dieplinger,Susanne Suessner,Marlies Antlanger,Daniel Cejka,Ioana Alesutan,Jakob Voelkl
BackgroundThe excessive cardiovascular mortality of patients with chronic kidney disease (CKD) could be linked to mineral stress, the biological consequence of calcium-phosphate nanoparticle exposure. This study investigated whether zinc is associated with mineral stress markers in CKD.MethodsZinc and T50 (serum calcification propensity) as well as hydrodynamic radius of secondary calciprotein particles (CPP2) were measured in blood donors and CKD patients with/out dialysis.ResultsSerum zinc concentrations and T50 were reduced, while CPP2 radius was increased in CKD patients. Serum zinc levels positively correlated with T50 and inversely correlated with CPP2 radius. In a hierarchical linear regression model, T50 was associated with age, calcium, phosphate, magnesium and albumin. Addition of zinc significantly improved prediction of the model, confirming an additional contribution of zinc to T50. Similar observations were made for the association of zinc and CPP2 radius, but spiking experiments indicated that zinc may stronger modify T50 than CPP2 radius. Also, urinary zinc excretion was increased in patients with kidney disease and correlated to T50 and CPP2 radius. Serum zinc further correlated with markers of arterial stiffness in blood donors and CKD patients, but these associations did not remain significant in a multivariate linear regression model.ConclusionsReduced serum zinc levels in CKD appear directly linked to lower T50 and associated with larger CPP2 radius. Further studies on the associations of zinc and mineral stress as well as putative therapeutic benefits of zinc supplementation are required.
背景慢性肾脏病(CKD)患者心血管死亡率过高可能与矿物质应激有关,而矿物质应激是纳米磷酸钙颗粒暴露的生物学后果。本研究探讨了锌是否与 CKD 患者的矿物质应激指标有关。结果CKD 患者的血清锌浓度和 T50(血清钙化倾向)以及二次钙蛋白颗粒(CPP2)的水动力半径均有所降低,而 CPP2 半径则有所增加。血清锌水平与 T50 呈正相关,与 CPP2 半径呈反相关。在分层线性回归模型中,T50 与年龄、钙、磷酸盐、镁和白蛋白相关。锌的加入明显改善了模型的预测结果,证实了锌对 T50 的额外贡献。锌与 CPP2 半径的关系也有类似的观察结果,但尖峰实验表明,锌可能比 CPP2 半径更能改变 T50。此外,肾病患者的尿锌排泄量增加,并与 T50 和 CPP2 半径相关。血清锌进一步与献血者和慢性肾脏病患者的动脉僵化指标相关,但这些关联在多变量线性回归模型中并不显著。需要进一步研究锌和矿物质应激的关系以及补锌的治疗作用。
{"title":"Association of serum zinc with mineral stress in chronic kidney disease.","authors":"Azmat Sohail,Jakob Obereigner,Gregor Mitter,Thomas Schmid,Anna-Sofie Hofer,Gerhard Schuster,Astrid Hügl,Angelika H Dorninger,Markus Mandl,Andreas Pasch,Helmut K Lackner,Ilona Papousek,Benjamin Dieplinger,Susanne Suessner,Marlies Antlanger,Daniel Cejka,Ioana Alesutan,Jakob Voelkl","doi":"10.1093/ckj/sfae258","DOIUrl":"https://doi.org/10.1093/ckj/sfae258","url":null,"abstract":"BackgroundThe excessive cardiovascular mortality of patients with chronic kidney disease (CKD) could be linked to mineral stress, the biological consequence of calcium-phosphate nanoparticle exposure. This study investigated whether zinc is associated with mineral stress markers in CKD.MethodsZinc and T50 (serum calcification propensity) as well as hydrodynamic radius of secondary calciprotein particles (CPP2) were measured in blood donors and CKD patients with/out dialysis.ResultsSerum zinc concentrations and T50 were reduced, while CPP2 radius was increased in CKD patients. Serum zinc levels positively correlated with T50 and inversely correlated with CPP2 radius. In a hierarchical linear regression model, T50 was associated with age, calcium, phosphate, magnesium and albumin. Addition of zinc significantly improved prediction of the model, confirming an additional contribution of zinc to T50. Similar observations were made for the association of zinc and CPP2 radius, but spiking experiments indicated that zinc may stronger modify T50 than CPP2 radius. Also, urinary zinc excretion was increased in patients with kidney disease and correlated to T50 and CPP2 radius. Serum zinc further correlated with markers of arterial stiffness in blood donors and CKD patients, but these associations did not remain significant in a multivariate linear regression model.ConclusionsReduced serum zinc levels in CKD appear directly linked to lower T50 and associated with larger CPP2 radius. Further studies on the associations of zinc and mineral stress as well as putative therapeutic benefits of zinc supplementation are required.","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 1","pages":"sfae258"},"PeriodicalIF":4.6,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142262466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-term peritoneal rest reduces peritoneal solute transport rate and increases ultrafiltration in high/high average transport peritoneal dialysis patients: a crossover randomized controlled trial. 短期腹膜休息可降低高/高平均转运率腹膜透析患者的腹膜溶质转运率并增加超滤量:一项交叉随机对照试验。
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-20 eCollection Date: 2024-09-01 DOI: 10.1093/ckj/sfae251
Bei Wu, Huiping Zhao, Li Zuo, Aichun Liu, Lixia Lu, Jie Qiao, Xinxin Chu, Chuncui Men, Yuting He

Background: The peritoneal solute transport rate (PSTR) tends to increase over time in some patients undergoing peritoneal dialysis (PD), potentially leading to ultrafiltration (UF) failure. Previous case reports have shown a significant decrease in PSTR and subsequent recovery of UF after discontinuing PD for a while. Therefore, we conducted a randomized controlled crossover study to evaluate the impact of short-term peritoneal rest on PSTR.

Methods: The study involved 14 continuous ambulatory peritoneal dialysis (CAPD) patients with high/high-average transport rate. Two groups were randomly assigned different treatment sequences: one group underwent daily intermittent peritoneal dialysis (IPD) for 4 weeks followed by CAPD, while the other group initially received CAPD treatment for 4 weeks and then switched to IPD. Peritoneal equilibration tests were performed before and after each treatment to evaluate PSTR and paired t-tests were used to compare the changes. Volume load, serum potassium and other clinical indicators were monitored at the same time.

Results: Short-term peritoneal rest (daily IPD) significantly reduced PSTR, with a decrease in the dialysate:plasma creatinine ratio from 0.71 ± 0.05 to 0.65 ± 0.07 (P < .001). Additionally, ultrafiltration significantly increased from 210 ± 165 ml to 407 ± 209 ml (P = .001). But there were no significant changes in interleukin-6 and vascular endothelial growth factor of PD effluent. No serious adverse events such as hypotension or hyperkalaemia occurred.

Conclusions: In PD patients with high and high-average transport, a 4-week period of short-term peritoneal rest by switching from CAPD to IPD (without long dwell) can lead to reductions in PSTR and increases in UF volumes, while maintaining clinical safety.

背景:一些接受腹膜透析(PD)的患者的腹膜溶质转运率(PSTR)往往会随着时间的推移而增加,从而可能导致超滤(UF)失败。以往的病例报告显示,在停止腹膜透析一段时间后,PSTR 会明显下降,超滤功能也会随之恢复。因此,我们进行了一项随机对照交叉研究,以评估短期腹膜休息对 PSTR 的影响:研究涉及 14 名高/高平均转运率的连续卧床腹膜透析(CAPD)患者。随机分配两组不同的治疗顺序:一组每天进行间歇性腹膜透析(IPD)4 周,然后进行 CAPD;另一组最初接受 CAPD 治疗 4 周,然后转为 IPD。每次治疗前后均进行腹膜平衡测试,以评估 PSTR,并采用配对 t 检验比较其变化。同时监测容量负荷、血清钾和其他临床指标:结果:短期腹膜休息(每日 IPD)可明显降低 PSTR,透析液:血浆肌酐比值从 0.71 ± 0.05 降至 0.65 ± 0.07(P = .001)。但透析液中的白细胞介素-6和血管内皮生长因子没有明显变化。没有发生低血压或高钾血症等严重不良事件:结论:对于高转运率和高平均转运率的腹膜透析患者,通过从 CAPD 转为 IPD(无需长时间停留),进行为期 4 周的短期腹膜休息,可降低 PSTR 和增加 UF 容量,同时保持临床安全性。
{"title":"Short-term peritoneal rest reduces peritoneal solute transport rate and increases ultrafiltration in high/high average transport peritoneal dialysis patients: a crossover randomized controlled trial.","authors":"Bei Wu, Huiping Zhao, Li Zuo, Aichun Liu, Lixia Lu, Jie Qiao, Xinxin Chu, Chuncui Men, Yuting He","doi":"10.1093/ckj/sfae251","DOIUrl":"https://doi.org/10.1093/ckj/sfae251","url":null,"abstract":"<p><strong>Background: </strong>The peritoneal solute transport rate (PSTR) tends to increase over time in some patients undergoing peritoneal dialysis (PD), potentially leading to ultrafiltration (UF) failure. Previous case reports have shown a significant decrease in PSTR and subsequent recovery of UF after discontinuing PD for a while. Therefore, we conducted a randomized controlled crossover study to evaluate the impact of short-term peritoneal rest on PSTR.</p><p><strong>Methods: </strong>The study involved 14 continuous ambulatory peritoneal dialysis (CAPD) patients with high/high-average transport rate. Two groups were randomly assigned different treatment sequences: one group underwent daily intermittent peritoneal dialysis (IPD) for 4 weeks followed by CAPD, while the other group initially received CAPD treatment for 4 weeks and then switched to IPD. Peritoneal equilibration tests were performed before and after each treatment to evaluate PSTR and paired <i>t</i>-tests were used to compare the changes. Volume load, serum potassium and other clinical indicators were monitored at the same time.</p><p><strong>Results: </strong>Short-term peritoneal rest (daily IPD) significantly reduced PSTR, with a decrease in the dialysate:plasma creatinine ratio from 0.71 ± 0.05 to 0.65 ± 0.07 (<i>P</i> < .001). Additionally, ultrafiltration significantly increased from 210 ± 165 ml to 407 ± 209 ml (<i>P</i> = .001). But there were no significant changes in interleukin-6 and vascular endothelial growth factor of PD effluent. No serious adverse events such as hypotension or hyperkalaemia occurred.</p><p><strong>Conclusions: </strong>In PD patients with high and high-average transport, a 4-week period of short-term peritoneal rest by switching from CAPD to IPD (without long dwell) can lead to reductions in PSTR and increases in UF volumes, while maintaining clinical safety.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"17 9","pages":"sfae251"},"PeriodicalIF":3.9,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11411283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association between klotho and kidney and cardiovascular outcomes: a comprehensive systematic review and meta-analysis Klotho与肾脏和心血管疾病结果的关系:一项全面的系统回顾和荟萃分析
IF 4.6 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-19 DOI: 10.1093/ckj/sfae255
Mehmet Kanbay, Crischentian Brinza, Lasin Ozbek, Mustafa Guldan, Uluman Sisman, Sidar Copur, Andreea Covic, Dragos-Viorel Scripcariu, Alexandru Burlacu, Adrian Covic
Background and Aim Chronic kidney disease (CKD) and end-stage renal disease (ESKD) are significant global health challenges associated with progressive kidney dysfunction and numerous complications, including cardiovascular disease and mortality. This study aims to explore the potential association between plasma Klotho levels and various prognostic outcomes in CKD and ESKD, including all-cause mortality, cardiovascular events, metabolic syndrome development, and adverse renal events necessitating renal replacement therapies. Materials and Methods A literature search was conducted up to June 3, 2024, using the electronic databases Cochrane Library, Ovid MEDLINE, CINAHL, Web of Science, SCOPUS, and PubMed. This systematic review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results Fourteen studies were included. For all-cause mortality, comparing CKD patients with low versus high Klotho levels showed a significant association (OR 1.81, 95% CI 1.34–2.44, p = 0.0001), with substantial heterogeneity (I2 = 69%). Excluding one study reduced heterogeneity (I2 = 43%) while maintaining significance (OR 1.97, 95% CI 1.45–2.66, p &lt; 0.0001). Cardiovascular mortality was higher in patients with low Klotho levels (OR 2.11, 95% CI 1.61–2.76, p &lt; 0.00001), with low heterogeneity (I2 = 25%). Excluding one study eliminated heterogeneity (I2 = 0%) while maintaining significance (OR 2.39, 95% CI 1.83–3.12, p &lt; 0.00001). Composite cardiovascular events did not differ significantly between low and high Klotho groups (OR 1.51, 95% CI 0.82–2.77, p = 0.18), but with high heterogeneity (I2 = 72%). Patients with low Klotho levels had a higher risk of adverse renal events (OR 2.36, 95% CI 1.37–4.08, p = 0.002), with moderate heterogeneity (I2 = 61%). Sensitivity analysis reduced heterogeneity (I2 = 0%) while maintaining significance (OR 3.08, 95% CI 1.96–4.85, p &lt; 0.00001). Specifically, for ESKD or kidney replacement therapy risk, low Klotho levels were associated with an increased risk (OR 2.30, 95% CI 1.26–4.21, p = 0.007). Similarly, CKD progression risk was higher in patients with lower Klotho levels (OR 2.48, 95% CI 1.45–4.23, p = 0.0009). Conclusion Lower serum Klotho levels serve as a significant predictor of adverse outcomes, including increased risks of all-cause mortality, cardiovascular mortality, and progression to end-stage kidney disease among CKD patients.
背景和目的 慢性肾脏病(CKD)和终末期肾脏病(ESKD)是全球面临的重大健康挑战,与进行性肾功能障碍和包括心血管疾病和死亡率在内的多种并发症有关。本研究旨在探讨血浆 Klotho 水平与 CKD 和 ESKD 的各种预后结果之间的潜在关联,包括全因死亡率、心血管事件、代谢综合征的发展以及需要进行肾脏替代治疗的不良肾脏事件。材料与方法 利用电子数据库 Cochrane Library、Ovid MEDLINE、CINAHL、Web of Science、SCOPUS 和 PubMed 进行了文献检索,截至 2024 年 6 月 3 日。本系统综述遵循系统综述和元分析首选报告项目(PRISMA)指南。结果 共纳入 14 项研究。在全因死亡率方面,比较 Klotho 水平低与高的 CKD 患者,结果显示两者有显著关联(OR 1.81,95% CI 1.34-2.44,p = 0.0001),但存在很大的异质性(I2 = 69%)。排除一项研究后,异质性降低(I2 = 43%),但仍保持显著性(OR 1.97,95% CI 1.45-2.66,p &lt; 0.0001)。Klotho水平低的患者心血管死亡率较高(OR 2.11,95% CI 1.61-2.76,pamp &;lt;0.00001),异质性较低(I2 = 25%)。排除一项研究可消除异质性(I2 = 0%),同时保持显著性(OR 2.39,95% CI 1.83-3.12,p &;lt;0.00001)。复合心血管事件在Klotho水平低和Klotho水平高两组之间无显著差异(OR 1.51,95% CI 0.82-2.77,p = 0.18),但异质性较高(I2 = 72%)。Klotho水平低的患者发生肾脏不良事件的风险更高(OR 2.36,95% CI 1.37-4.08,p = 0.002),异质性为中度(I2 = 61%)。敏感性分析降低了异质性(I2 = 0%),同时保持了显著性(OR 3.08,95% CI 1.96-4.85,p &lt; 0.00001)。具体而言,就 ESKD 或肾脏替代治疗风险而言,低 Klotho 水平与风险增加相关(OR 2.30,95% CI 1.26-4.21,p = 0.007)。同样,Klotho 水平较低的患者的 CKD 进展风险也较高(OR 2.48,95% CI 1.45-4.23,p = 0.0009)。结论 血清 Klotho 水平较低可显著预测不良后果,包括增加 CKD 患者的全因死亡率、心血管死亡率和进展为终末期肾病的风险。
{"title":"The association between klotho and kidney and cardiovascular outcomes: a comprehensive systematic review and meta-analysis","authors":"Mehmet Kanbay, Crischentian Brinza, Lasin Ozbek, Mustafa Guldan, Uluman Sisman, Sidar Copur, Andreea Covic, Dragos-Viorel Scripcariu, Alexandru Burlacu, Adrian Covic","doi":"10.1093/ckj/sfae255","DOIUrl":"https://doi.org/10.1093/ckj/sfae255","url":null,"abstract":"Background and Aim Chronic kidney disease (CKD) and end-stage renal disease (ESKD) are significant global health challenges associated with progressive kidney dysfunction and numerous complications, including cardiovascular disease and mortality. This study aims to explore the potential association between plasma Klotho levels and various prognostic outcomes in CKD and ESKD, including all-cause mortality, cardiovascular events, metabolic syndrome development, and adverse renal events necessitating renal replacement therapies. Materials and Methods A literature search was conducted up to June 3, 2024, using the electronic databases Cochrane Library, Ovid MEDLINE, CINAHL, Web of Science, SCOPUS, and PubMed. This systematic review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results Fourteen studies were included. For all-cause mortality, comparing CKD patients with low versus high Klotho levels showed a significant association (OR 1.81, 95% CI 1.34–2.44, p = 0.0001), with substantial heterogeneity (I2 = 69%). Excluding one study reduced heterogeneity (I2 = 43%) while maintaining significance (OR 1.97, 95% CI 1.45–2.66, p &amp;lt; 0.0001). Cardiovascular mortality was higher in patients with low Klotho levels (OR 2.11, 95% CI 1.61–2.76, p &amp;lt; 0.00001), with low heterogeneity (I2 = 25%). Excluding one study eliminated heterogeneity (I2 = 0%) while maintaining significance (OR 2.39, 95% CI 1.83–3.12, p &amp;lt; 0.00001). Composite cardiovascular events did not differ significantly between low and high Klotho groups (OR 1.51, 95% CI 0.82–2.77, p = 0.18), but with high heterogeneity (I2 = 72%). Patients with low Klotho levels had a higher risk of adverse renal events (OR 2.36, 95% CI 1.37–4.08, p = 0.002), with moderate heterogeneity (I2 = 61%). Sensitivity analysis reduced heterogeneity (I2 = 0%) while maintaining significance (OR 3.08, 95% CI 1.96–4.85, p &amp;lt; 0.00001). Specifically, for ESKD or kidney replacement therapy risk, low Klotho levels were associated with an increased risk (OR 2.30, 95% CI 1.26–4.21, p = 0.007). Similarly, CKD progression risk was higher in patients with lower Klotho levels (OR 2.48, 95% CI 1.45–4.23, p = 0.0009). Conclusion Lower serum Klotho levels serve as a significant predictor of adverse outcomes, including increased risks of all-cause mortality, cardiovascular mortality, and progression to end-stage kidney disease among CKD patients.","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"25 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of SGLT2 inhibitors on parameters of renal venous congestion in intrarenal Doppler ultrasonography. SGLT2 抑制剂对肾内多普勒超声检查中肾静脉充血参数的影响
IF 4.6 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-14 DOI: 10.1093/ckj/sfae234
Manuel Wallbach,Jamil Ajrab,Bilgin Bayram,Dennis Pieper,Ann-Kathrin Schäfer,Stephan Lüders,Fani Delistefani,Dieter Müller,Michael Koziolek
BackgroundCardiorenal syndrome is a common condition in clinical practice in which renal venous congestion (VC) plays an important role. Intrarenal Doppler ultrasound (IRD) is a non-invasive method to assess and quantify renal VC. The current study aims to investigate the effects of SGLT2 inhibitor (SGLT2i) therapy on IRD parameters of renal VC.MethodsThis prospective observational study included patients with chronic kidney disease (CKD) with or without type 2 diabetes mellitus and/or heart failure (HF) with reduced and preserved ejection fraction who had an indication for standard of care SGLT2i therapy. IRD, assessing venous impedance index (VII), and intrarenal venous flow pattern (IRVF) analysis were performed within the interlobar vessels of the right kidney before and 6 months after initiation of SGLT2i therapy.ResultsA number of 64 patients with CKD and a cardiorenal risk profile were included (mean eGFR 42.9 ml/min/1.73 m2; 56% with HF, and 38% with type 2 diabetes mellitus). 17 patients exhibited signs of VC in the IRD. VII was significantly correlated with levels of NT-proBNP, female gender, NYHA class, and was significantly negative correlated with body mass index. After 6 months, a notable decrease in the mean VII of the right interlobar veins by 0.13 (P < .01) was observed. Stratification according to IRVF pattern showed a significant shift towards reduced renal VC pattern after 6 months (P = .03).ConclusionsIn this study, SGLT2i therapy resulted in a reduction in renal VC as assessed by IRD. These findings underscore the potential haemodynamic benefits of SGLT2 inhibitors in cardiorenal syndrome and warrant further investigation into their clinical implications.
背景心肾综合征是临床上的一种常见病,肾静脉充血(VC)在其中起着重要作用。肾内多普勒超声(IRD)是一种评估和量化肾静脉充血的无创方法。本研究旨在探讨 SGLT2 抑制剂(SGLT2i)治疗对 IRD 肾脏 VC 参数的影响。方法这项前瞻性观察性研究纳入了有 SGLT2i 标准疗法适应症的慢性肾脏病(CKD)伴或不伴 2 型糖尿病和/或射血分数降低和保留射血分数的心力衰竭(HF)患者。结果 共纳入了 64 名患有慢性肾脏病和心肾风险的患者(平均 eGFR 42.9 毫升/分钟/1.73 平方米;56% 患有心力衰竭,38% 患有 2 型糖尿病)。17 名患者在 IRD 中显示出 VC 的迹象。VII 与 NT-proBNP 水平、女性性别、NYHA 分级有明显相关性,与体重指数呈明显负相关。6 个月后,观察到右叶间静脉的平均 VII 明显下降了 0.13(P < .01)。根据 IRVF 模式进行的分层显示,6 个月后,肾脏 VC 模式明显向减少方向转变(P = .03)。这些发现强调了 SGLT2 抑制剂对心肾综合征潜在的血流动力学益处,值得进一步研究其临床意义。
{"title":"Effects of SGLT2 inhibitors on parameters of renal venous congestion in intrarenal Doppler ultrasonography.","authors":"Manuel Wallbach,Jamil Ajrab,Bilgin Bayram,Dennis Pieper,Ann-Kathrin Schäfer,Stephan Lüders,Fani Delistefani,Dieter Müller,Michael Koziolek","doi":"10.1093/ckj/sfae234","DOIUrl":"https://doi.org/10.1093/ckj/sfae234","url":null,"abstract":"BackgroundCardiorenal syndrome is a common condition in clinical practice in which renal venous congestion (VC) plays an important role. Intrarenal Doppler ultrasound (IRD) is a non-invasive method to assess and quantify renal VC. The current study aims to investigate the effects of SGLT2 inhibitor (SGLT2i) therapy on IRD parameters of renal VC.MethodsThis prospective observational study included patients with chronic kidney disease (CKD) with or without type 2 diabetes mellitus and/or heart failure (HF) with reduced and preserved ejection fraction who had an indication for standard of care SGLT2i therapy. IRD, assessing venous impedance index (VII), and intrarenal venous flow pattern (IRVF) analysis were performed within the interlobar vessels of the right kidney before and 6 months after initiation of SGLT2i therapy.ResultsA number of 64 patients with CKD and a cardiorenal risk profile were included (mean eGFR 42.9 ml/min/1.73 m2; 56% with HF, and 38% with type 2 diabetes mellitus). 17 patients exhibited signs of VC in the IRD. VII was significantly correlated with levels of NT-proBNP, female gender, NYHA class, and was significantly negative correlated with body mass index. After 6 months, a notable decrease in the mean VII of the right interlobar veins by 0.13 (P < .01) was observed. Stratification according to IRVF pattern showed a significant shift towards reduced renal VC pattern after 6 months (P = .03).ConclusionsIn this study, SGLT2i therapy resulted in a reduction in renal VC as assessed by IRD. These findings underscore the potential haemodynamic benefits of SGLT2 inhibitors in cardiorenal syndrome and warrant further investigation into their clinical implications.","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"64 1","pages":"sfae234"},"PeriodicalIF":4.6,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney transplantation and gut microbiota. 肾移植与肠道微生物群
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-14 eCollection Date: 2024-08-01 DOI: 10.1093/ckj/sfae214
Zehuan Chen, Xinhua Chang, Qianyu Ye, Yifang Gao, Ronghai Deng

Kidney transplantation is an effective way to improve the condition of patients with end-stage renal disease. However, maintaining long-term graft function and improving patient survival remain a key challenge after kidney transplantation. Dysbiosis of intestinal flora has been reported to be associated with complications in renal transplant recipients. The commensal microbiota plays an important role in the immunomodulation of the transplant recipient responses. However, several processes, such as the use of perioperative antibiotics and high-dose immunosuppressants in renal transplant recipients, can lead to gut dysbiosis and disrupt the interaction between the microbiota and the host immune responses, which in turn can lead to complications such as infection and rejection in organ recipients. In this review, we summarize and discuss the changes in intestinal flora and their influencing factors in patients after renal transplantation as well as the evidence related to the impact of intestinal dysbiosis on the prognosis of renal transplantation from in vivo and clinical studies, and conclude with a discussion of the use of microbial therapy in the transplant population. Hopefully, a deeper understanding of the function and composition of the microbiota in patients after renal transplantation may assist in the development of clinical strategies to restore a normal microbiota and facilitate the clinical management of grafts in the future.

肾移植是改善终末期肾病患者病情的有效方法。然而,维持长期移植物功能和提高患者存活率仍是肾移植术后面临的主要挑战。据报道,肠道菌群失调与肾移植受者的并发症有关。共生微生物群在移植受体反应的免疫调节中发挥着重要作用。然而,一些过程,如肾移植受者围手术期抗生素和大剂量免疫抑制剂的使用,可导致肠道菌群失调,破坏微生物群与宿主免疫反应之间的相互作用,进而导致器官受者出现感染和排斥等并发症。在这篇综述中,我们总结并讨论了肾移植后患者肠道菌群的变化及其影响因素,以及体内和临床研究中与肠道菌群失调对肾移植预后的影响有关的证据,最后还讨论了在移植人群中使用微生物疗法的问题。希望对肾移植后患者体内微生物群的功能和组成有更深入的了解,这将有助于制定临床策略来恢复正常的微生物群,并促进未来对移植物的临床管理。
{"title":"Kidney transplantation and gut microbiota.","authors":"Zehuan Chen, Xinhua Chang, Qianyu Ye, Yifang Gao, Ronghai Deng","doi":"10.1093/ckj/sfae214","DOIUrl":"10.1093/ckj/sfae214","url":null,"abstract":"<p><p>Kidney transplantation is an effective way to improve the condition of patients with end-stage renal disease. However, maintaining long-term graft function and improving patient survival remain a key challenge after kidney transplantation. Dysbiosis of intestinal flora has been reported to be associated with complications in renal transplant recipients. The commensal microbiota plays an important role in the immunomodulation of the transplant recipient responses. However, several processes, such as the use of perioperative antibiotics and high-dose immunosuppressants in renal transplant recipients, can lead to gut dysbiosis and disrupt the interaction between the microbiota and the host immune responses, which in turn can lead to complications such as infection and rejection in organ recipients. In this review, we summarize and discuss the changes in intestinal flora and their influencing factors in patients after renal transplantation as well as the evidence related to the impact of intestinal dysbiosis on the prognosis of renal transplantation from <i>in vivo</i> and clinical studies, and conclude with a discussion of the use of microbial therapy in the transplant population. Hopefully, a deeper understanding of the function and composition of the microbiota in patients after renal transplantation may assist in the development of clinical strategies to restore a normal microbiota and facilitate the clinical management of grafts in the future.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"17 8","pages":"sfae214"},"PeriodicalIF":3.9,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11336673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Point-of-care ultrasound Training in Nephrology: a position statement by the International Alliance for POCUS in Nephrology 肾脏病护理点超声波培训:国际肾脏病护理点超声波联盟立场声明
IF 4.6 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-14 DOI: 10.1093/ckj/sfae245
Abhilash Koratala, Eduardo R Argaiz, Gregorio Romero-González, Nathaniel Reisinger, Siddiq Anwar, William Beaubien-Souligny, Bhavna Bhasin-Chhabra, Hugo Diniz, Marco Antonio Vaco Gallardo, Fredzzia Graterol Torres, Faeq Husein-Syed, Jennifer Hanko, Aala Jaberi, Amir Kazory, Rupesh Raina, Claudio Ronco, Octavio J Salgado, Sidharth Kumar Sethi, Vanessa Villavicencio Cerón, Manjusha Yadla, Marcus Gomes Bastos
Point-of-care Ultrasonography (POCUS) has rapidly evolved from a niche technology to an indispensable tool across medical specialties, including nephrology. This evolution is driven by advancements in technology and the visionary efforts of clinicians in emergency medicine and beyond. Recognizing its potential, medical schools are increasingly integrating POCUS into training curricula, emphasizing its role in enhancing diagnostic accuracy and patient care. Despite these advancements, barriers such as limited faculty expertise and standardized guidelines hinder widespread adoption and regulation. The International Alliance for POCUS in Nephrology (IAPN), through this position statement, aims to guide nephrologists in harnessing the diagnostic power of POCUS responsibly and effectively. By outlining core competencies, recommending training modalities, and advocating for robust quality assurance measures, we envision a future where POCUS enhances nephrology practice globally, ensuring optimal patient outcomes through informed, evidence-based decision-making. International collaboration and education are essential to overcome current challenges and realize the full potential of POCUS in nephrology and beyond.
护理点超声造影 (POCUS) 已从一项小众技术迅速发展成为包括肾脏病学在内的各医学专科不可或缺的工具。技术的进步和急诊医学及其他领域临床医生的远见卓识推动了这一发展。医学院认识到了 POCUS 的潜力,正越来越多地将其纳入培训课程,强调其在提高诊断准确性和患者护理方面的作用。尽管取得了这些进步,但师资力量和标准化指南有限等障碍阻碍了其广泛应用和规范。国际肾脏病学 POCUS 联盟 (IAPN) 通过本立场声明,旨在指导肾脏病学家负责任地、有效地利用 POCUS 的诊断能力。通过概述核心能力、推荐培训模式和倡导强有力的质量保证措施,我们展望未来,POCUS 将在全球范围内提高肾脏病学的实践水平,通过知情、循证的决策确保患者获得最佳治疗效果。国际合作和教育对于克服当前的挑战并充分发挥 POCUS 在肾脏病学及其他领域的潜力至关重要。
{"title":"Point-of-care ultrasound Training in Nephrology: a position statement by the International Alliance for POCUS in Nephrology","authors":"Abhilash Koratala, Eduardo R Argaiz, Gregorio Romero-González, Nathaniel Reisinger, Siddiq Anwar, William Beaubien-Souligny, Bhavna Bhasin-Chhabra, Hugo Diniz, Marco Antonio Vaco Gallardo, Fredzzia Graterol Torres, Faeq Husein-Syed, Jennifer Hanko, Aala Jaberi, Amir Kazory, Rupesh Raina, Claudio Ronco, Octavio J Salgado, Sidharth Kumar Sethi, Vanessa Villavicencio Cerón, Manjusha Yadla, Marcus Gomes Bastos","doi":"10.1093/ckj/sfae245","DOIUrl":"https://doi.org/10.1093/ckj/sfae245","url":null,"abstract":"Point-of-care Ultrasonography (POCUS) has rapidly evolved from a niche technology to an indispensable tool across medical specialties, including nephrology. This evolution is driven by advancements in technology and the visionary efforts of clinicians in emergency medicine and beyond. Recognizing its potential, medical schools are increasingly integrating POCUS into training curricula, emphasizing its role in enhancing diagnostic accuracy and patient care. Despite these advancements, barriers such as limited faculty expertise and standardized guidelines hinder widespread adoption and regulation. The International Alliance for POCUS in Nephrology (IAPN), through this position statement, aims to guide nephrologists in harnessing the diagnostic power of POCUS responsibly and effectively. By outlining core competencies, recommending training modalities, and advocating for robust quality assurance measures, we envision a future where POCUS enhances nephrology practice globally, ensuring optimal patient outcomes through informed, evidence-based decision-making. International collaboration and education are essential to overcome current challenges and realize the full potential of POCUS in nephrology and beyond.","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"26 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduced renal function is associated with faster loss of bone mineral density in patients with non-dialysis CKD 肾功能减退与非透析性慢性肾功能衰竭患者骨矿物质密度流失加快有关
IF 4.6 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-14 DOI: 10.1093/ckj/sfae248
Dong Hoon Kang, Cheol Ho Park, Hyung Woo Kim, Jung Tak Park, Seung Hyeok Han, Jayoun Kim, Jong Cheol Jeong, Yaeni Kim, Soo Wan Kim, Kook-Hwan Oh, Shin-Wook Kang, Tae-Hyun Yoo
Background Bone mineral density (BMD) predicts fracture risk in patients with chronic kidney disease (CKD) and in the general population. However, few studies have investigated risk factors for bone loss in patients with CKD. The aim of this study was to investigate whether renal function is associated with the rate of BMD decline. Methods A prospective cohort study included 1 006 patients with CKD stages 2–4 between 2011 and 2016. BMD was measured using dual-energy X-ray absorptiometry at baseline and 4 years. The eGFR was measured 2–6 times during the 4-year follow-up. We analyzed the decline in bone mineral density according to CKD stage and further compared the rate of BMD decline according to eGFR trajectories at each stage. Results Advanced CKD stage was associated with a faster rate of decline in total hip BMD (stage 2: −0.23, stage 3A: −0.39, stage 3B: −0.80, stage 4: −1.23% change/year in men [p &lt; 0.001]; stage 2: −0.86, stage 3A: −1.19, stage 3B: −1.20, stage 4: −1.58% change/year in women [p &lt; 0.03]). Two distinct eGFR trajectories (Class 1: stable group; Class 2: rapid decline group) were observed. The rapid decline group showed a trend toward an increased rate of decline in total hip BMD. Subgroup analysis according to eGFR trajectories revealed a significant difference in BMD decline rate between stable and rapid decline groups. Conclusions Advanced CKD stage and accelerated decline in renal function were associated with rapid BMD decline in non-dialysis patients with CKD.
背景 骨矿物质密度(BMD)可预测慢性肾脏病(CKD)患者和普通人群的骨折风险。然而,很少有研究对 CKD 患者骨质流失的风险因素进行调查。本研究旨在探讨肾功能是否与 BMD 的下降速度有关。方法 一项前瞻性队列研究纳入了 2011 年至 2016 年间的 1006 名 2-4 期 CKD 患者。在基线和 4 年时使用双能 X 射线吸收测量法测量 BMD。在 4 年的随访期间,对 eGFR 进行了 2-6 次测量。我们根据 CKD 阶段分析了骨矿物质密度的下降情况,并根据每个阶段的 eGFR 轨迹进一步比较了 BMD 的下降率。结果 CKD 晚期与总髋骨矿物质密度下降速度较快有关联(2 期:-0.23,3A 期:-0.23,3B 期:-0.23):-0.23,3A 阶段-0.39,3B 阶段3B期:-0.80,4期:-1.23男性每年变化-1.23% [pamp;lt;0.001];阶段 2:-0.86,3A 阶段:-1.19,3B 阶段:-1.23-0.86,第 3A 阶段:-1.19,第 3B 阶段:-1.20,第 4 阶段:-1.23-0.86,3A 阶段:-1.19,3B 阶段:-1.20,4:女性的变化率为-1.58%/年 [pamp&;lt;0.03])。观察到两种不同的 eGFR 变化轨迹(1 级:稳定组;2 级:快速下降组)。快速下降组显示出总髋关节 BMD 下降率增加的趋势。根据 eGFR 轨迹进行的分组分析显示,稳定组和快速下降组的 BMD 下降率存在显著差异。结论 在非透析的慢性肾脏病患者中,慢性肾脏病晚期和肾功能加速衰退与 BMD 快速下降有关。
{"title":"Reduced renal function is associated with faster loss of bone mineral density in patients with non-dialysis CKD","authors":"Dong Hoon Kang, Cheol Ho Park, Hyung Woo Kim, Jung Tak Park, Seung Hyeok Han, Jayoun Kim, Jong Cheol Jeong, Yaeni Kim, Soo Wan Kim, Kook-Hwan Oh, Shin-Wook Kang, Tae-Hyun Yoo","doi":"10.1093/ckj/sfae248","DOIUrl":"https://doi.org/10.1093/ckj/sfae248","url":null,"abstract":"Background Bone mineral density (BMD) predicts fracture risk in patients with chronic kidney disease (CKD) and in the general population. However, few studies have investigated risk factors for bone loss in patients with CKD. The aim of this study was to investigate whether renal function is associated with the rate of BMD decline. Methods A prospective cohort study included 1 006 patients with CKD stages 2–4 between 2011 and 2016. BMD was measured using dual-energy X-ray absorptiometry at baseline and 4 years. The eGFR was measured 2–6 times during the 4-year follow-up. We analyzed the decline in bone mineral density according to CKD stage and further compared the rate of BMD decline according to eGFR trajectories at each stage. Results Advanced CKD stage was associated with a faster rate of decline in total hip BMD (stage 2: −0.23, stage 3A: −0.39, stage 3B: −0.80, stage 4: −1.23% change/year in men [p &amp;lt; 0.001]; stage 2: −0.86, stage 3A: −1.19, stage 3B: −1.20, stage 4: −1.58% change/year in women [p &amp;lt; 0.03]). Two distinct eGFR trajectories (Class 1: stable group; Class 2: rapid decline group) were observed. The rapid decline group showed a trend toward an increased rate of decline in total hip BMD. Subgroup analysis according to eGFR trajectories revealed a significant difference in BMD decline rate between stable and rapid decline groups. Conclusions Advanced CKD stage and accelerated decline in renal function were associated with rapid BMD decline in non-dialysis patients with CKD.","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"47 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic targets in membranous nephropathy: plasma cells and complement. 膜性肾病的治疗目标:浆细胞和补体。
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-13 eCollection Date: 2024-09-01 DOI: 10.1093/ckj/sfae243
Nicola M Tomas

Membranous nephropathy (MN) is an antibody-mediated autoimmune disease and the most common cause of nephrotic syndrome in adults. The discovery of phospholipase A2 receptor 1 (PLA2R1) as the first target antigen in patients with MN 15 years ago has led to a paradigm shift in the pathobiological understanding of this disease. Autoantibodies against PLA2R1 as well as thrombospondin type-1 domain-containing 7A, the second identified antigen in adults, were shown to be disease-causing and act through local activation of the complement system, primarily via the classical and lectin pathways. These findings indicate that both plasma cells, the main source of antibodies and autoantibodies, as well as the complement system, the main pathogenic effector mechanism in MN, are rational and pathogenesis-based treatment targets in MN. This review summarizes pathomechanistic and clinical evidence for and against plasma cell- and complement-targeted treatments in MN.

膜性肾病(MN)是一种抗体介导的自身免疫性疾病,也是成人肾病综合征最常见的病因。15 年前发现磷脂酶 A2 受体 1(PLA2R1)是膜性肾病患者的第一个靶抗原,这导致了对该病病理生物学认识的范式转变。针对 PLA2R1 和凝血酶原 1 型结构域的 7A 的自身抗体(成人中第二个确定的抗原)被证明是致病的,并主要通过经典途径和凝集素途径通过局部激活补体系统发挥作用。这些发现表明,抗体和自身抗体的主要来源--浆细胞以及MN的主要致病效应机制--补体系统都是MN的合理和基于发病机制的治疗目标。本综述总结了支持和反对以浆细胞和补体为靶点治疗 MN 的病理机制和临床证据。
{"title":"Therapeutic targets in membranous nephropathy: plasma cells and complement.","authors":"Nicola M Tomas","doi":"10.1093/ckj/sfae243","DOIUrl":"10.1093/ckj/sfae243","url":null,"abstract":"<p><p>Membranous nephropathy (MN) is an antibody-mediated autoimmune disease and the most common cause of nephrotic syndrome in adults. The discovery of phospholipase A2 receptor 1 (PLA2R1) as the first target antigen in patients with MN 15 years ago has led to a paradigm shift in the pathobiological understanding of this disease. Autoantibodies against PLA2R1 as well as thrombospondin type-1 domain-containing 7A, the second identified antigen in adults, were shown to be disease-causing and act through local activation of the complement system, primarily via the classical and lectin pathways. These findings indicate that both plasma cells, the main source of antibodies and autoantibodies, as well as the complement system, the main pathogenic effector mechanism in MN, are rational and pathogenesis-based treatment targets in MN. This review summarizes pathomechanistic and clinical evidence for and against plasma cell- and complement-targeted treatments in MN.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"17 9","pages":"sfae243"},"PeriodicalIF":3.9,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of quality of life on the survival of elderly patients with end-stage renal disease: a prospective multicenter cohort study in Korea. 生活质量对终末期肾病老年患者生存期的影响:韩国一项前瞻性多中心队列研究。
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-13 eCollection Date: 2024-09-01 DOI: 10.1093/ckj/sfae241
Yu-Kyung Chung, Jeong-Hoon Lim, Ye-Na Jeon, You Hyun Jeon, Hee-Yeon Jung, Ji-Young Choi, Sun-Hee Park, Chan-Duck Kim, Yong-Lim Kim, Jang-Hee Cho

Background: Quality of life (QOL) is associated with mortality in dialysis patients. However, the impact of QOL index or score on elderly patients undergoing maintenance dialysis is unclear. We analyzed the relationship between QOL domains and survival in elderly end-stage renal disease (ESRD) patients on dialysis.

Methods: We included 492 incident ESRD patients aged ≥65 years from a Korean nationwide prospective cohort study who were assessed for QOL with a follow-up duration of 67.3 ± 34.6 months after dialysis initiation. Their QOL was evaluated using the Kidney Disease Quality of Life (KDQOL) instrument, and the effect of each QOL domain on mortality was analyzed. Multivariable Cox regression analysis was performed to identify independent risk factors for death after adjusting for confounding factors.

Results: Low physical component summary (PCS) and Short Form-36 score were significantly associated with low survival rate (< .001 and = .017, respectively), whereas the mental component summary and ESRD-targeted item scores were not correlated with survival rate. Multivariable Cox regression analysis confirmed that only a high PCS score was associated with better survival (hazard ratio 0.71; 95% confidence interval 0.52-0.97; = .031). Linear regression analysis revealed that age, sex, modified Charlson comorbidity index, albumin and intact parathyroid hormone were associated with PCS. Among the PCS items, only the physical functioning score was significantly associated with mortality (= .017).

Conclusion: PCS was an independent risk factor for death in elderly ESRD patients. A higher physical functioning score was associated with a better outcome, suggesting the importance of physical condition in elderly dialysis patients.

背景:生活质量(QOL)与透析患者的死亡率有关。然而,QOL 指数或评分对接受维持性透析的老年患者的影响尚不明确。我们分析了老年终末期肾病(ESRD)透析患者的 QOL 领域与生存之间的关系:我们从一项韩国全国性前瞻性队列研究中纳入了 492 名年龄≥65 岁的 ESRD 患者,对他们进行了 QOL 评估,随访时间为开始透析后 67.3 ± 34.6 个月。使用肾脏疾病生活质量(KDQOL)工具对他们的 QOL 进行了评估,并分析了每个 QOL 领域对死亡率的影响。在调整了混杂因素后,进行了多变量考克斯回归分析,以确定死亡的独立风险因素:结果:低体能部分摘要(PCS)和 Short Form-36 评分与低存活率显著相关(P P = .017,分别),而精神部分摘要和 ESRD 目标项目评分与存活率无关。多变量 Cox 回归分析证实,只有 PCS 高分才与较高的生存率相关(危险比 0.71;95% 置信区间 0.52-0.97;P = 0.031)。线性回归分析显示,年龄、性别、改良夏尔森合并症指数、白蛋白和完整甲状旁腺激素与 PCS 相关。在 PCS 项目中,只有身体功能评分与死亡率有显著相关性(P = .017):结论:PCS是老年ESRD患者死亡的独立风险因素。结论:PCS 是老年 ESRD 患者死亡的独立危险因素,身体功能得分越高,预后越好,这表明身体状况对老年透析患者非常重要。
{"title":"The impact of quality of life on the survival of elderly patients with end-stage renal disease: a prospective multicenter cohort study in Korea.","authors":"Yu-Kyung Chung, Jeong-Hoon Lim, Ye-Na Jeon, You Hyun Jeon, Hee-Yeon Jung, Ji-Young Choi, Sun-Hee Park, Chan-Duck Kim, Yong-Lim Kim, Jang-Hee Cho","doi":"10.1093/ckj/sfae241","DOIUrl":"10.1093/ckj/sfae241","url":null,"abstract":"<p><strong>Background: </strong>Quality of life (QOL) is associated with mortality in dialysis patients. However, the impact of QOL index or score on elderly patients undergoing maintenance dialysis is unclear. We analyzed the relationship between QOL domains and survival in elderly end-stage renal disease (ESRD) patients on dialysis.</p><p><strong>Methods: </strong>We included 492 incident ESRD patients aged ≥65 years from a Korean nationwide prospective cohort study who were assessed for QOL with a follow-up duration of 67.3 ± 34.6 months after dialysis initiation. Their QOL was evaluated using the Kidney Disease Quality of Life (KDQOL) instrument, and the effect of each QOL domain on mortality was analyzed. Multivariable Cox regression analysis was performed to identify independent risk factors for death after adjusting for confounding factors.</p><p><strong>Results: </strong>Low physical component summary (PCS) and Short Form-36 score were significantly associated with low survival rate (<i>P </i>< .001 and <i>P </i>= .017, respectively), whereas the mental component summary and ESRD-targeted item scores were not correlated with survival rate. Multivariable Cox regression analysis confirmed that only a high PCS score was associated with better survival (hazard ratio 0.71; 95% confidence interval 0.52-0.97; <i>P </i>= .031). Linear regression analysis revealed that age, sex, modified Charlson comorbidity index, albumin and intact parathyroid hormone were associated with PCS. Among the PCS items, only the physical functioning score was significantly associated with mortality (<i>P </i>= .017).</p><p><strong>Conclusion: </strong>PCS was an independent risk factor for death in elderly ESRD patients. A higher physical functioning score was associated with a better outcome, suggesting the importance of physical condition in elderly dialysis patients.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"17 9","pages":"sfae241"},"PeriodicalIF":3.9,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semaglutide associated kidney injury 塞马鲁肽相关肾损伤
IF 4.6 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-08-13 DOI: 10.1093/ckj/sfae250
Farhana Begum, Kelly Chang, Krishna Kapoor, Rajiv Vij, Gautam Phadke, Wesley M Hiser, Rimda Wanchoo, Purva Sharma, Nirja Sutaria, Kenar D Jhaveri
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are multipurpose agents effective in improving glycemic control in patients with type 2 diabetes while also achieving weight loss and risk reduction of major cardiovascular (CV) events and chronic kidney disease(CKD) progression. With their increased utility in diabetes, obesity, CV health, and renal protection, the use of GLP1-agonists have increased. However, with this increased use, there have also been increased reports of associated kidney adverse events including case reports of acute interstitial nephritis (AIN) associated with GLP-1RA use. We report the data from the FDA adverse event reporting system (FAERS) in relation to GLP-1RA use and adverse kidney events, with AKI being the most common. In addition, we report two cases of semaglutide associated biopsy-proven AIN and one with associated podocytopathy. To our knowledge, this is the first case of biopsy-proven AIN with podocytopathy associated with semaglutide use. Both patients experienced complete remission shortly after discontinuing semaglutide and undergoing immunosuppressive therapy. Further analysis of the FAERS database, revealed 17 cases of proteinuria and 1 case of glomerulonephritis associated with semaglutide in the FAERS database, however no further information was available. While further research is needed to establish causality, this case series adds to the growing body of literature that semaglutide is associated with AIN and adds a new association, semaglutide with AIN and podocytopathies. While the overall clinical and mortality benefits of GLP-1RAs may outweigh the rarer risks, prescribers need to be aware of these associations, particularly as the use of GLP-1RAs continues to expand.
胰高血糖素样肽-1 受体激动剂(GLP-1RAs)是一种多用途药物,能有效改善 2 型糖尿病患者的血糖控制,同时还能减轻体重,降低主要心血管(CV)事件和慢性肾病(CKD)恶化的风险。随着 GLP1- 激动剂在糖尿病、肥胖症、心血管健康和肾脏保护方面的作用越来越大,其用量也越来越多。然而,随着使用的增加,相关肾脏不良事件的报告也在增加,包括与使用 GLP-1RA 相关的急性间质性肾炎 (AIN) 的病例报告。我们报告了 FDA 不良事件报告系统(FAERS)中有关 GLP-1RA 使用和肾脏不良事件的数据,其中 AKI 最为常见。此外,我们还报告了两例与舍马鲁肽相关的活组织检查证实的 AIN,以及一例与相关的荚膜细胞病变。据我们所知,这是首例经活检证实的AIN伴有荚膜细胞病变并与使用塞马鲁肽有关的病例。两名患者在停用塞马鲁肽并接受免疫抑制治疗后不久,病情都得到了完全缓解。对 FAERS 数据库的进一步分析显示,FAERS 数据库中有 17 例蛋白尿病例和 1 例肾小球肾炎病例与使用塞马鲁肽有关,但没有进一步的信息。虽然还需要进一步研究才能确定因果关系,但本系列病例为越来越多的文献增添了新的内容,即塞马鲁肽与AIN有关,并增加了一个新的关联,即塞马鲁肽与AIN和荚膜细胞病变有关。虽然 GLP-1RAs 在临床和死亡率方面的总体益处可能大于罕见的风险,但处方者需要注意这些关联,尤其是随着 GLP-1RAs 的使用范围不断扩大。
{"title":"Semaglutide associated kidney injury","authors":"Farhana Begum, Kelly Chang, Krishna Kapoor, Rajiv Vij, Gautam Phadke, Wesley M Hiser, Rimda Wanchoo, Purva Sharma, Nirja Sutaria, Kenar D Jhaveri","doi":"10.1093/ckj/sfae250","DOIUrl":"https://doi.org/10.1093/ckj/sfae250","url":null,"abstract":"Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are multipurpose agents effective in improving glycemic control in patients with type 2 diabetes while also achieving weight loss and risk reduction of major cardiovascular (CV) events and chronic kidney disease(CKD) progression. With their increased utility in diabetes, obesity, CV health, and renal protection, the use of GLP1-agonists have increased. However, with this increased use, there have also been increased reports of associated kidney adverse events including case reports of acute interstitial nephritis (AIN) associated with GLP-1RA use. We report the data from the FDA adverse event reporting system (FAERS) in relation to GLP-1RA use and adverse kidney events, with AKI being the most common. In addition, we report two cases of semaglutide associated biopsy-proven AIN and one with associated podocytopathy. To our knowledge, this is the first case of biopsy-proven AIN with podocytopathy associated with semaglutide use. Both patients experienced complete remission shortly after discontinuing semaglutide and undergoing immunosuppressive therapy. Further analysis of the FAERS database, revealed 17 cases of proteinuria and 1 case of glomerulonephritis associated with semaglutide in the FAERS database, however no further information was available. While further research is needed to establish causality, this case series adds to the growing body of literature that semaglutide is associated with AIN and adds a new association, semaglutide with AIN and podocytopathies. While the overall clinical and mortality benefits of GLP-1RAs may outweigh the rarer risks, prescribers need to be aware of these associations, particularly as the use of GLP-1RAs continues to expand.","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"9 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Kidney Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1